Edition:
United States

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

3.19USD
28 Jun 2017
Change (% chg)

-- (--)
Prev Close
$3.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
403,585
52-wk High
$3.24
52-wk Low
$0.98

ATRS.OQ

Chart for ATRS.OQ

About

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection... (more)
No analyst recommendations are available for ATRS.OQ.

Overall

Beta: 0.28
Market Cap(Mil.): €437.24
Shares Outstanding(Mil.): 155.93
Dividend: --
Yield (%): --

Financials

  ATRS.OQ Industry Sector
P/E (TTM): -- 34.19 19.05
EPS (TTM): -3.04 -- --
ROI: -- 13.11 -5.05
ROE: -- 15.61 -4.28

BRIEF-Antares Pharma announces debt financing from Hercules Capital

* Antares Pharma announces debt financing from Hercules Capital

Jun 07 2017

BRIEF-Antares Pharma files $200 mln mixed shelf

* Files for mixed shelf of up to $200 million - sec filing Source text for Eikon: Further company coverage:

May 09 2017

BRIEF-Antares Pharma reports Q1 loss per share $0.03

* Antares Pharma reports first quarter 2017 operating and financial results

May 09 2017

BRIEF-Antares Pharma Q4 loss per share $0.03

* Antares pharma reports fourth quarter and full year 2016 operating and financial results

Mar 14 2017

BRIEF-Antares Pharma reported a preliminary net loss per share of $0.03

* Antares Pharma Inc - company reported preliminary total revenue of $14.2 million and $52.2 million for quarter and year ended december 31, 2016, respectively

Mar 06 2017

BRIEF-Antares Pharma announces FDA acceptance of new drug application for Quickshot testosterone

* Antares Pharma announces FDA acceptance of new drug application for Quickshot testosterone Source text for Eikon: Further company coverage:

Feb 27 2017

More From Around the Web

Earnings vs. Estimates

No consensus analysis data available.